Validation of genomics-based prognostic tests in malignant pleural mesothelioma

Clinical Cancer Research

Volumn 11, Issue 12, 2005, Pages 4406-4414

  Gordon, Gavin J ^a   Rockwell, Graham N ^a   Godfrey, Paul A ^a   Jensen, Roderick V ^b   Glickman, Jonathan N ^a   Yeap, Beow Y ^c   Richards, William G ^a   Sugarbaker, David J ^a   Bueno, Raphael ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DNA MICROARRAY; GENE EXPRESSION; GENOMICS; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VALIDATION PROCESS;

ADULT; AGED; COHORT STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MESOTHELIOMA; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLEURAL NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS;

EID: 20444366275     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2181     Document Type: Article

References (26)

1. Pass H. Malignant pleural mesothelioma: surgical roles and novel therapies. Clin Lung Cancer 2001;3:102-17.
2. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
3. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345:535-9.
4. Sugarbaker DJ, Liptay MJ. Therapeutic approaches in malignant mesothelioma. In: Aisner J, Arriagada R, Green MR, Martini N, Perry MC, editors. Comprehensive textbook of thoracic oncology. Baltimore (MD): Williams and Wilkins; 1996. p. 786-98.
5. Aisner J. Diagnosis, staging, and natural history of pleural mesothelioma. In: Aisner J, Arriagada R, Green MR, Martini N, Perry MC, editors. Comprehensive textbook of thoracic oncology. Baltimore (MD): Williams and Wilkins; 1996. p. 799-85.
6. Britton M. The Epidemiology of Mesothelioma. Semin Surg Oncol 2002;29:18-25.
7. Corson JM, Renshaw AA. Pathology of mesothelioma. In: Aisner J, Arriagada R, Green MR, Martini N, Perry MC, editors. Comprehensive textbook of thoracic oncology. Baltimore (MD): Williams and Wilkins; 1996. p. 757-8.
8. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 1996;224:288-94.
9. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
10. Gordon GJ, Jensen RV, Hsiao L-L, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002;62:4963-7.
11. Gordon GJ, Hsiao L-L, Jensen RV, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003;95:598-6058.
12. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004;10:849-59.
13. Venables WN, Riley BD. Modern applied statistics with S-Plus. New York: Springer; 1997.
14. Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MT, Bueno R. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev 2003;12:905-10.
15. Bueno R, Loughlin KR, Powell MH, Gordon GJ. A diagnostic test for prostate cancer from gene expression profiling data. J Urol 2004;171:903-6.
16. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
17. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65.
18. Gullans SR. Of microarrays and meandering data points. Nat Genet 2000;26:4-5.
19. Funakoshi T, Tachibana I, Hoshida Y, et al. Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 2003;22:674-87.
20. Murayama Y, Miyagawa J, Shinomura Y, et al. Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 2002;98:505-13.
21. Sauer G, Kurzeder C, Grundmann R, et al. Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. Oncol Rep 2003;10:405-10.
22. Ordonez NG. The value of antibodies 44-36A, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Am J Surg Pathol 1997;21:1399-408.
23. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-51.
24. Acebo E, Val-Bernal JF, Gomez-Roman JJ. Thrombomodulin, calretinin and c-kit (CD117) expression in cardiac myxoma. Histol Histopathol 2001;16:1031-6.
25. Kristiansen G, Schluns K, Yongwei Y, et al. CD24 is an independent prognostic marker of survival in non-small cell lung cancer patients. Br J Cancer 2003;88:231-6.
26. Kristiansen G, Denkert C, Schluns K, et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002;161:1215-21.